Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study - Biesdorf, Carla; Guan, Xiaowen; Siddani, Satya R.; Hoffman, David; Boehm, Nils; Medeiros, Bruno C.; Doi, Toshihiko; de Jonge, Maja; Rasco, Drew; Menon, Rajeev M.; Polepally, Akshanth R. (Cancer chemotherapy and pharmacology, 2024)
Keywords: 5-Fluorouracil; Adult; agonists; Antibodies; Antineoplastic Agents - adverse effects; Apoptosis; Bevacizumab; Blood cancer; Bridged Bicyclo Compounds, Heterocyclic; Cancer Research; Chemotherapy; Clinical outcomes; death domain receptors; Dosage; Drug dosages; fluorouracil; half life; Hematologic Neoplasms - drug therapy; Hematology; Humans; Immune response; Immunogenicity; intravenous injection; Irinotecan; ligands; Malignancy; Medicine; Medicine & Public Health; Monoclonal antibodies; NCT; NCT03082209; necrosis; neoplasms; Neoplasms - drug therapy; Neoplasms - pathology; Oncology; Original Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacovigilance; Solid tumors; Sulfonamides; TRAIL protein; Tumor cells; Tumors; Immunogenicity; Pharmacokinetics; Eftozanermin alfa; Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)